Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil extends weekly gains as Iran conflict rages on, with crude surging around 18% Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Stokes Frank sells Castle Biosciences stock worth $192k By Insider Trading Published 03/05/2026, 07:23 PM Stokes Frank sells Castle Biosciences stock worth $192k 0 CSTL -0.92% Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares of common stock on March 3, 2026, in two separate transactions. The sales were executed at prices ranging from $27.32 to $27.81, netting Stokes approximately $192,073. The timing coincides with recent volatility, as the stock has declined 5.6% over the past week, according to InvestingPro data, though shares remain up 35.6% over the past year. The first sale involved 5,300 shares sold at a weighted average price of $27.32, with prices ranging from $26.70 to $27.67. The second sale consisted of 1,700 shares at a weighted average price of $27.81, with prices ranging from $27.72 to $27.97. On March 3 and 4, Stokes also disposed of 14,343 shares of common stock valued at $401,875 to cover tax obligations. Additionally, on March 4, Stokes acquired 27,946 shares of Castle Biosciences common stock through option exercises, and received 48,367 Restricted Stock Units. Despite recent weakness, InvestingPro analysis suggests the stock trades below its Fair Value, placing it among undervalued opportunities . For deeper insights, investors can access the comprehensive Pro Research Report, available for CSTL and 1,400+ US equities. In other recent news, Castle Biosciences reported its fourth-quarter 2025 financial results, surpassing both earnings and revenue expectations. The company posted a diluted loss per share of $0.08, which was significantly better ...